-
Tonghua Golden-Horse Pharmaceutical Embraces AI with DeepSeek R1 for Drug Innovation
•
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (SHE: 000766) recently held a special meeting to deploy the implementation of the DeepSeek R1 large model, chaired by Chairman Zhang Yufu. The company aims to accelerate the development and commercialization of the SPT-07A project through AI technology, marking a significant step in its…
-
DeepSeek’s Rise in the Pharmaceutical Industry: A New Era of AI-Driven Transformation
•
The emergence of DeepSeek-R1 during the Lunar New Year celebrations marked a pivotal moment in the adoption of affordable, open-source large language models (LLMs). This breakthrough not only lowered the barrier to entry for AI technology but also demonstrated its remarkable potential to revolutionize workflows across industries. The pharmaceutical sector…
-
Quantum Hi-Tech and ECNU Establish AI-Driven Drug Manufacturing Lab
•
CRO+CDMO Quantum Hi-Tech (China) Biotechnology Co., Ltd (ChemPartner, SHE: 300149) announced plans to establish an AI drug intelligent manufacturing joint laboratory with East China Normal University (ECNU), a comprehensive research-oriented university in Shanghai. This collaboration aims to set a new paradigm for school-enterprise cooperation in the field of AI-driven pharmaceutical…
-
Insilico Medicine Closes USD110 Million Series E Round to Advance AI-Driven Drug Pipeline
•
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced the completion of a USD110 million Series E financing round. The round was led by a private equity fund of Value Partners Group (HKG: 0806), with participation from Shanghai Pudong Venture Investment, Shanghai Pudong Development (Group), Wuxi Innovation Investment, and Yixing…
-
MindRank Ltd Receives FDA Clearance for MRANK-106 Clinical Study in Solid Tumors
•
China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd announced receiving clearance from the US Food and Drug Administration (FDA) to initiate a clinical study for its MRANK-106, a dual inhibitor of WEE1 and YES1 kinases. This marks a significant milestone for the company as it expands its innovative oncology pipeline…
-
Nona Biosciences Launches Hu-mAtrIx: AI-Driven Engine for Accelerated Antibody Drug Discovery
•
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced the introduction of Hu-mAtrIx, an innovative AI-assisted drug discovery engine. This platform marks a significant advancement in the field of antibody development, leveraging cutting-edge technology to enhance efficiency and success rates. Integrated Antibody Discovery PlatformNona’s Hu-mAtrIx platform enables…
-
Roche Launches Genentech Innovation Center in Boston to Accelerate Drug Development
•
Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston. This new facility aims to strengthen longstanding partnerships in disease biology, engineering, and artificial intelligence/machine learning. CVRM Hub and AI IntegrationThe center will serve as Roche’s…
-
SonoScape Medical Corp. Wins First AI-Powered Prenatal Ultrasound Approval in China
•
Shenzhen-based SonoScape Medical Corp. announced receiving marketing approval in China for its S-Fetus prenatal ultrasound product. This makes it the first domestic firm to gain approval for an artificial intelligence (AI)-empowered prenatal ultrasound device in the country. Technology Integration and AdvantagesThe device deeply integrates ultrasound technology and AI, representing the…
-
Insilico Medicine’s AI-Discovered Drug Rentosertib Approved for Clinical Trials
•
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced approval by the United States Adopted Names (USAN) Council to name its ISM001-055 as rentosertib. This groundbreaking drug candidate for idiopathic pulmonary fibrosis (IPF) represents a milestone in AI-driven drug discovery. Rentosertib’s Development and Clinical ResultsRentosertib is the world’s first drug…
-
Insilico Medicine and Tenacia Partner on AI-Driven CNS Therapies
•
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has formed a partnership with compatriot firm Tenacia, a central nervous system (CNS) specialist incubated by Bain Capital. The collaboration aims to integrate Insilico’s cutting-edge generative AI drug discovery platform Pharma AI with Tenacia’s proprietary data assets to develop small molecule inhibitors…
-
Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies
•
US-based AI-powered biotech Gensaic, Inc. announced the signing of a licensing and discovery cooperation agreement with Denmark-based Novo Nordisk A/S (NYSE: NVO). The collaboration, combining Novo’s deep therapeutic knowledge and drug development experience with Gensaic’s novel protein design technology, is designed to discover tissue-targeting ligands and develop new therapeutic candidates…
-
Baidu Health Partners with Jolly Pharma to Boost Digital Drug Marketing
•
Baidu Health, an internet giant, has entered into a partnership with Zhejiang Jolly Pharmaceutical Co., Ltd. Under the agreement, Baidu will leverage its strengths in AI and its internet medicine platform to drive digital marketing innovation for Jolly Pharma’s Bailing capsules and other drugs. The initial focus will be on…
-
AI in Healthcare: Accelerating Applications in Diagnostics and Multi-omics Analysis
•
The breakthrough technology of DeepSeek has significantly accelerated the application of AI in the medical industry, opening up diverse application scenarios for AI + healthcare. IVD companies are leveraging AI-empowered products and services to reduce costs and increase efficiency. New algorithms are helping to speed up the integration and application…
-
Biocytogen Completes DeepSeek Localization, Integrates with “Thousand Mice, Ten Thousand Antibodies” Plan
•
On February 28, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that it has completed the localization deployment of DeepSeek and achieved full synergy with its core business, the “Thousand Mice, Ten Thousand Antibodies” program. This technological integration marks a new stage of intelligence and dataization in the early –…
-
Ping An Good Doctor Launches AI-Powered Digital Doctor Service
•
China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as Ping An Good Doctor, announced the launch of “Ping An Xin Yi,” an AI-powered digital doctor service integrated within its Ping An Health APP. The service offers 24/7 access to AI-assisted health consultations, marking a significant step…
-
AWS Collaborates with MSK to Accelerate Oncology Research via AI and Cloud Tech
•
Amazon Web Services (AWS) announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK), a world-leading cancer research institute based in New York. The partnership aims to leverage artificial intelligence (AI), high-performance computing (HPC), and cloud technologies to drive breakthroughs in oncology research and personalized treatment development. Collaboration DetailsAWS…
-
Zhejiang Dian Diagnostics Partners with Best Covered to Tackle Alzheimer’s Disease
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a China-based medical diagnostics firm, has formed a strategic partnership with Shanghai-based Best Covered, a technology company specializing in Alzheimer’s disease (AD). The collaboration aims to enhance early screening, precise testing, personalized intervention, and digital management of AD. Partnership GoalsThe two companies will…
-
AIM Vaccine Leverages DeepSeek AI to Optimize mRNA Shingles Vaccine Design
•
China-based AIM Vaccine Co., Ltd (HKG: 6660) has filed its mRNA-based shingles vaccine with the U.S. Food and Drug Administration (FDA), marking a milestone for the company’s entry into the global vaccine market. The submission follows promising preclinical data and positions AIM as a pioneer in mRNA shingles vaccine development,…
-
AI in Healthcare: The Impact of DeepSeek Technology and Industry Developments
•
The integration of advanced AI technologies into healthcare is revolutionizing the industry, and the recent developments involving DeepSeek technology have further amplified this transformation. As highlighted by policy updates and industry trends, AI-powered solutions are gaining momentum across various sectors of healthcare, from diagnostics to drug discovery. This article explores…
-
Harbour BioMed and Insilico Medicine Partner on AI-Powered Antibody Development
•
China-based Harbour BioMed (HKG: 2142) announced a strategic partnership with Insilico Medicine, a generative artificial intelligence (AI)-driven biotech firm. The collaboration aims to leverage their respective strengths in antibody discovery and AI to accelerate the development of innovative therapeutic antibodies. Partnership DetailsThe partnership combines Harbour BioMed’s industry-leading technology platform, proprietary…
